º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Tech

Newcastle fintech firm ION seals £1.3m deal with pharmaceutical giant Quotient Sciences

The deal comes as ION looks to expand its team after seeing strong growth last year

Rob Mathieson, managing director of ION(Image: Publicity Pic)

North East fintech firm ION has secured a three-year contract with drug developer Quotient Sciences worth £1.3m.

The company has offices in Gosforth and London and works with mid-market businesses to deploy advanced accounting, billing, and CRM cloud applications.

Now, the business has secured the deal with Quotient Sciences, focused on transforming Quotient’s CRM and financial technology solutions, to create a unified cloud platform to support the company’s growth.

Read more: Find more North East business news here

Pharmaceutical firm Quotient Sciences provides drug substance, drug product and clinical testing services from seven bases across the º£½ÇÊÓÆµ and US, including Alnwick, Northumberland, where it is investing more than £6m into the North East operations it acquired from Arcinova at the start of last year.

Working with ION to bring its customer relations and fintech services under one organization will allow it to save customers’ time and money in getting new medicines to patients faster.

Managing director Rob Mathieson said: “ION is delighted to be partnering with Quotient Sciences to deliver this transformative project.

"Their industry-leading solution will bring all company activities and intelligence into one platform, improving efficiency and driving growth across their business.